Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.

Trial Details

NCT ID
NCT05305924
Phase
PHASE2
Sponsor
The Methodist Hospital Research Institute
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Fulvestrant Run-In
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Male or Female \>18 years of age on the day of informed consent signing.
  • Progression on a CDK4/6 inhibitor in combination with an AI immediately prior to the enrollment on this study
  • Histologically confirmed ER-positive, HER2-negative metastatic breast cancer. ER-positive is defined as ≥1% immunohistochemical (IHC) staining of a…
  • IHC 1+ or 0

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →